You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
Time- and cost-saving generation of glycan variants to facilitate drug development.
Optimized glycosylation without compromising other CQAs or product yield.
Improved lot-to-lot consistency to reduce risk of product quality variation and resulting delays.
Generation of glycoprofiles which may not otherwise be generated.
Streamlined analytics in comparability studies.
",
"Country": "XG",
"Code": "Benefits",
"Name": "Benefits"
},
{
"Language": "en",
"Value": "β-1,4-Galactosyltransferase, rec. EQ is a highly active recombinant human glycosyltransferase, expressed in CHO cells.
To use in vitro glycoengineering in drug development and manufacturing processes, enzymes should be of enhanced quality (EQ), compared to enzymes used in early R&D or analytical applications: Enzymes should be tested for host-cell impurities and relevant metal impurities and be available at least in gram amounts. β-1,4-Galactosyltransferase, rec. EQ fulfills those criteria and can also be provided in GMP Grade upon request.",
"Country": "XG",
"Code": "Product Description",
"Name": "Product Description"
},
{
"Language": "en",
"Value": "Incubation of β-1,4-Galactosyltransferase and UDP-Galactose with a glycoprotein leads to increased galactosylation of the glycoprotein.",
"Country": "XG",
"Code": "Applications",
"Name": "Applications"
},
{
"Language": "en",
"Value": "Appearance: Clear and colorless to slightly yellowish solution. Specific activity: >12 U/mg Protein (OD 280 nm) A280 = 0.984: 15 ± 1.5 mg/mL Purity (HPLC): >90% Bioburden: ≤100 CFU/mL Endotoxin: ≤10 EU/mg Host cell protein: ≤ 4000 ppm Host cell DNA: ≤ 100 pg/mg Heavy metal: (Cd, Co, V, Ni, Ag, Se); ≤ 10 ppm Stability: At –15 to –25°C within specification range for 18 months (08 098 182 103) and 12 months (08 098 182 101).",
"Country": "XG",
"Code": "Specification",
"Name": "Specification"
}
]
}
}
]
}
